Dallas BioPharma Closes $23M Series C Funding

by | Sep 21, 2023
Osteal Therapeutics, a clinical-stage biopharmaceutical company, says it's developing "a new category" of combination therapies for orthopedic infections. The new funding round, led by Asteroid Partners, will help Osteal accelerate preparation for commercial launch of VT-X7, its lead therapy for the treatment of periprosthetic joint infection, the company said.
VanTrust Real Estate Announces New Science, Technology Division
by | Jun 6, 2023

VanTrust Real Estate, which has an office in Dallas, has announced a new division that is designed to match its real estate expertise and capital resources with both public and private sector clients in the life sciences, R&D, institutional, governmental, biotech, pharmaceutical and technology industries....

Biote Enlists Healthcare Veteran to Drive Men’s Hormone Therapy Expansion
by | Apr 14, 2023

Irving-based Biote Corporation, a preventive healthcare solutions provider that delivers personalized hormone therapy, has appointed John Denne as general manager of its men’s health division. The move is aimed at expanding the company’s presence in the growing market for male hormone replacement therapy....

Dallas’ Lupagen Aims To Change the Way Cancer, Other Disorders Are Treated
by | Jun 2, 2022
Instead of shipping a patient's blood to a lab for customized cell therapy, Lupagen does the procedure "in vivo," using a dialysis-like treatment at the patient's bedside. Now it's collaborating with Umoja Biopharma to use its drug-delivery tech to place targeted immunotherapies in patients.

“We're able to deliver different types of gene therapies in a closed system," Lupagen's CEO says, calling the tech a "bridge to the future."